Skip to content

Immune based therapies: Australian studies highlight new approaches

Evidence of 3TC resistance after treatment interruptions

Fifth Resistance Workshop Begins In Scottsdale, Arizona

Transmission of unusual HIV variants may increase risk of treatment failure

Resistance after nevirapine prophylaxis appears more common in women with HIV subtype D

Boosted NRTIs may overcome resistance and toxicity

Adefovir for hep B: not an HIV resistance risk

Treatment interruptions: no addition to viral reservoir seen

Global AIDS and Health Fund: what is it?

Direct to consumer drug ads coming soon in Europe?

Vaccine call for action: add your voice by June 25

Drug access table: June 2001 update

UK doubles commitment to Global Fund

UN Declaration of Commitment on HIV/AIDS

Diagnosed late: missed opportunities for care and prevention

New protease inhibitors at Buenos Aires conference

Educational interventions improve adherence to HAART

BHIVA clinicians feedback from Buenos Aires